Jeff Yass’s Gain Therapeutics GANX Stock Holding History

Jeff Yass’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Sell	78,206 -353,061	-82%	-$651K	﹤0.01%	12157
2026 Q1	$837K	Sell	431,267 -253,082	-37%	-$551K	﹤0.01%	8369
2025 Q4	$2.2M	Buy	684,349 +603,914	+751%	+$1.61M	﹤0.01%	5449
2025 Q3	$142K	Buy	80,435 +884	+1%	+$1.49K	﹤0.01%	11321
2025 Q2	$143K	Sell	79,551 -6,407	-7%	-$11.8K	﹤0.01%	11533
2025 Q1	$164K	Buy	85,958 +39,045	+83%	+$86.6K	﹤0.01%	11137
2024 Q4	$101K	Buy	+46,913	New	+$94.2K	﹤0.01%	11337
2024 Q2	–	Sell	-43,062	Closed	-$162K	–	12429
2024 Q1	$162K	Buy	43,062 +8,562	+25%	+$35.5K	﹤0.01%	10829
2023 Q4	$113K	Sell	34,500 -30,726	-47%	-$85.4K	﹤0.01%	11228
2023 Q3	$211K	Sell	65,226 -4,564	-7%	-$17.3K	﹤0.01%	10121
2023 Q2	$313K	Buy	69,790 +54,618	+360%	+$267K	﹤0.01%	9347
2023 Q1	$73.1K	Buy	+15,172	New	+$62K	﹤0.01%	11508
2022 Q1	–	Sell	-19,357	Closed	-$103K	–	13332
2021 Q4	$103K	Buy	+19,357	New	+$134K	﹤0.01%	12127

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's GANX Position: Q2 2026 in Review

Jeff Yass reduced its Gain Therapeutics (GANX) stake by 82% in Q2 2026, selling an estimated $651K and leaving 78,206 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #12157.

Jeff Yass first reported a position in GANX in Q4 2021 and has held it in 13 quarters since. The position peaked at $2.2M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Jeff Yass held 78,206 shares of Gain Therapeutics worth $159K as of Q2 2026.
Jeff Yass sold 353,061 Gain Therapeutics shares in Q2 2026, an estimated $651K.
Gain Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12157 holding.
Jeff Yass first reported a position in Gain Therapeutics in Q4 2021 and has held it in 13 quarters since.
Jeff Yass's Gain Therapeutics position peaked at $2.2M in Q4 2025.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.